Concepts (64)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 3 | 2026 | 526 | 0.660 |
Why?
|
| Splenic Neoplasms | 1 | 2018 | 7 | 0.570 |
Why?
|
| Mannose-Binding Lectins | 1 | 2018 | 21 | 0.560 |
Why?
|
| Hemangioma | 1 | 2018 | 27 | 0.550 |
Why?
|
| Lectins, C-Type | 1 | 2018 | 80 | 0.540 |
Why?
|
| Antigens, CD | 1 | 2018 | 344 | 0.510 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 22 | 0.480 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2016 | 25 | 0.470 |
Why?
|
| Influenza B virus | 1 | 2016 | 10 | 0.470 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 233 | 0.460 |
Why?
|
| Carcinoma | 1 | 2016 | 130 | 0.460 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 77 | 0.460 |
Why?
|
| Influenza A virus | 1 | 2016 | 122 | 0.430 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 514 | 0.430 |
Why?
|
| Influenza, Human | 1 | 2016 | 212 | 0.390 |
Why?
|
| Lung | 1 | 2016 | 969 | 0.330 |
Why?
|
| Internship and Residency | 1 | 2016 | 802 | 0.280 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2026 | 5 | 0.240 |
Why?
|
| SMARCB1 Protein | 1 | 2026 | 13 | 0.240 |
Why?
|
| Mutation | 2 | 2025 | 2672 | 0.240 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 93 | 0.210 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 1172 | 0.210 |
Why?
|
| Dioxygenases | 1 | 2024 | 36 | 0.200 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2023 | 10 | 0.200 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2025 | 314 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2025 | 193 | 0.190 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 124 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2026 | 1226 | 0.170 |
Why?
|
| Immunoconjugates | 1 | 2021 | 95 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 67 | 0.160 |
Why?
|
| Frozen Sections | 1 | 2016 | 11 | 0.120 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 101 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2025 | 5657 | 0.120 |
Why?
|
| Lung Neoplasms | 1 | 2023 | 710 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 289 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 106 | 0.110 |
Why?
|
| Young Adult | 2 | 2026 | 4855 | 0.100 |
Why?
|
| Humans | 8 | 2026 | 65654 | 0.100 |
Why?
|
| Adolescent | 2 | 2026 | 6350 | 0.090 |
Why?
|
| Female | 5 | 2026 | 34310 | 0.090 |
Why?
|
| Curriculum | 1 | 2016 | 609 | 0.090 |
Why?
|
| Adult | 4 | 2025 | 17511 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2016 | 731 | 0.090 |
Why?
|
| Male | 5 | 2026 | 31297 | 0.080 |
Why?
|
| Aged | 3 | 2025 | 15090 | 0.080 |
Why?
|
| Middle Aged | 3 | 2025 | 18440 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2026 | 184 | 0.050 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2024 | 35 | 0.050 |
Why?
|
| Alleles | 1 | 2025 | 455 | 0.050 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2024 | 82 | 0.050 |
Why?
|
| Radius | 1 | 2023 | 20 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 316 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2025 | 898 | 0.050 |
Why?
|
| Phenotype | 1 | 2026 | 1235 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 344 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2024 | 351 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 75 | 0.040 |
Why?
|
| Prognosis | 1 | 2025 | 1791 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2026 | 2076 | 0.040 |
Why?
|
| Disease Progression | 1 | 2024 | 1227 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2026 | 1561 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 466 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 875 | 0.030 |
Why?
|
| Child | 1 | 2026 | 4634 | 0.030 |
Why?
|